2022 Virtual Molecular Tumor Board Series

This webinar is part one of the four-part virtual molecular tumor board series.

In this session, our expert panelists will review patient cases in which multiomic profiling has identified biomarkers that may or may not aid clinicians in making treatment decisions.

Precision oncology has seen a natural maturation from guiding therapy decisions based only on testing of specific, largely hotspot DNA mutations to testing that integrates assessment of sequence mutations, structural changes (i.e., deletions, amplifications, fusions), RNA, and protein levels. There are also genomic signatures, such as tumor mutation burden (TMB) and microsatellite instability (MSI), that have further clinical implications in a pan-solid tumor setting.

While these multiple layers of biomarker information have the potential to better inform individualized treatment plans and patient outcomes, they have also made it more difficult for oncologists to readily interpret test results and make clinical decisions. Our panel will discuss in detail several clinical cases where multiomic profiling was conducted and used to recommend a course of treatment for patients based on the available data.

The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

This webinar is part two of the four-part virtual molecular tumor board series.

In this session, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency (HRD).

HRD is known to be a source of risk for heritable malignancies, such as breast and ovarian cancer. Increasing use of genomic sequencing combined with novel clinical development strategies is now expanding the types of cancer that are known to have an HRD subset and may respond to certain treatment regimens. 

Recently, oral PARP inhibitors have been approved, with the greatest activity observed in patients with HRD tumors. While a family of genes implicated in homologous recombination repair (HRR) have been associated with HRD (and related risk of malignancy), the impact of these genes on the activity of PARP inhibitors is still under study. This has increased the clinical challenges for interpretation of next-generation sequencing HRD results for many oncologists, as they try to keep up with which genes to act upon, when to refer a patient for genetic counseling, and how to prioritize HRD-associated therapy with other treatments that may be options based on a patient’s comprehensive genomic profile.

Our panel will address these challenges within the context of specific clinical cases. The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

This webinar is part three of the four-part virtual molecular tumor board series.

In this session, our expert panelists will review patient cases in which genomic profiling has identified structural variants with possible clinical relevance.

Improvements in nucleic acid sequencing technology have made the routine detection of structural alterations such as gene fusions, amplifications, and genomic instability signatures possible. In particular, the clinical relevance of gene fusions has expanded, resulting in both FDA-approved and clinically supported treatment options. Additionally, the increased utilization of comprehensive genomic analyses has the potential to inform a broad range of co-occurring somatic and germline alterations that may be associated with hereditary disease, therapeutic selection, and resistance to treatments.

However, this technological progress has increased clinical challenges for oncologists, as they try to keep up with therapeutic opportunities and understand how to prioritize treatment options amid other biomarker-informed therapies that could also potentially benefit patients based on their comprehensive genomic profiling results.

Our panel will address these challenges and opportunities within the context of specific clinical cases. The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.

This webinar is part four of our four-part virtual molecular tumor board series.

In this session, our expert panelists will review patient cases in which genomic profiling has identified activating mutations in the RAS or MEK pathways.

Molecular alterations in growth factor cell signaling pathways have been observed for most cancers and have led to novel treatment strategies. These pathways are often influenced by activating mutations in the RAS family and/or MEK-mediated signaling. There are now inhibitors of MEK and RAS family members (including the KRAS G12C mutation) with emerging clinical treatment strategies using novel combinations.

Clinical challenges for oncologists related to interpretation of these findings have increased as they try to keep up with the therapeutic options, specifically, when to apply them, and how to prioritize RAS/MEK related genes in the context of other alterations that are revealed in patients' comprehensive genomic profiling reports.

Our panel will address these challenges within the context of specific clinical cases. The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.